Common germline genetic variation impacts on the development of cancer and 94 common variants have now been identified, which together explain almost 20% of the variance in breast cancer risk. Up to 75% of breast cancer patients are likely to have radiotherapy and, depending on the country of treatment, up to 80% of patients survive breast cancer. For over 20 years clinicians have been concerned that the biological mechanisms underlying genetic predisposition to breast cancer risk may also increase radiosensitivity, such that some patients receiving breast tumor radiotherapy may be at increased risk of normal tissue toxicity. We have tested the breast cancer risk variants, both individually and as a multi-SNP risk profile, for association with acute and late radiotherapy toxicity phenotypes in 1,160 breast cancer patients. Our study showed that those with a high polygenic risk of breast cancer do not have increased risk of radiotherapy toxicity.
Introduction
To date, 94 common breast cancer susceptibility loci have been confirmed (p-value<5 x 10 -8 ) via metaanalyses of 11 genome wide association studies (GWAS; 15,748 cases and 18,084 controls) and 41 studies in the Breast Cancer Association Consortium (BCAC; 46,785 cases and 42,892 controls) (1) (2) (3) .
The effect sizes of each locus are generally modest with odds ratios (ORs) ≤1.34. It is estimated that 16% of the familial risk of breast cancer can be explained by common genetic variation (3) . In a recent study, single nucleotide polymorphism (SNP) markers of 77 confirmed breast cancer susceptibility loci were combined to create a polygenic risk score for breast cancer (4) . Women in the highest 1% of the risk score were 3.6 times more likely to develop breast cancer than women in the middle quintile (4) .
Radiation exposure is a known risk factor for the development of breast cancer (5) and individuals with the disease have been reported to have increased radiosensitivity (6) postulated as due to inherited defects in cellular responses to DNA damage from either endogenous or exogenous sources (7) . It has also been suggested that elevated radiosensitivity may be a marker of low penetrance predisposition to cancer (8) . Since radiosensitive individuals are more likely to experience toxicity following radiotherapy (9) , it has been hypothesized that genetic variants that predispose to breast cancer may also increase the risk of radiation side-effects. This hypothesis was based on the assumption that gene variants involved in cancer pre-disposition may have roles in both tumor formation and in the response to radiation-induced DNA damage.
We have tested this hypothesis using data from the UK RAPPER (Radiogenomics: Assessment of Polymorphisms for Predicting the Effects of Radiotherapy) study (10) . Common genetic variants individually have small effects on risk of breast cancer and are likely to have similarly small effects on radiotherapy toxicity. Thus, in order to search for evidence of associations with radiosensitivity, we Research.
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Materials and Methods

Patients
The UK RAPPER (UKCRN1471) study recruits patients from clinical trials and observational studies involving radiotherapy given with curative intent. This study comprised 1160 female breast cancer patients who were included in a GWAS described elsewhere, which provides details on the cohorts included (11): 937 patients from the Cambridge Breast IMRT Trial, 167 from the RACE (Radiation Complications and Epidemiology) study and 56 from a prospective study at the Christie Hospital, Manchester. Briefly, all patients underwent conservative surgery followed by adjuvant radiotherapy with doses of: 40 Gy in 15 fractions over three weeks (Cambridge Breast IMRT trial, Christie Hospital); 50 Gy in 25 fractions or 39.0 Gy/42.9 Gy in 13 fractions over five weeks (RACE study). An alpha/beta ratio of 3.4 (12) was used to calculate equivalent dose in 2Gy fraction for these schedules for inclusion in multivariable analyses. Patient characteristics and treatment factors are summarized in Table 1 .
Assessment of Radiotherapy Toxicity
Late toxicity data were collected prospectively using standardized scoring systems ( Supplementary   Table 1 ). This study used toxicity data collected at two specific time points: two years and five years following radiotherapy. Two-year telangiectasia, breast edema, photographically assessed shrinkage, toxicity (13). Acute toxicity was recorded for 920 patients in the Cambridge Breast IMRT Trial at 3 weeks following radiotherapy, using the Radiation Therapy Oncology Group (RTOG) scoring system (see Supplementary Table 2 ).
Genotyping, Quality Control and Imputation
Genotyping and imputation across the whole genome was performed for the RAPPER GWAS. Samples were genotyped using the Illumina CytoSNP12 (Illumina, San Diego, CA, USA). Standard quality control procedures were applied to remove variants that were missing in >5% of samples; had a minor allele frequency (MAF) < 1%; or had MAF<5% and were also missing in >1% samples. Variants were also removed if their genotype frequencies deviated from those expected under Hardy-Weinberg equilibrium (p-value < 10 -6 ). Samples were removed that had >3% of all variants missing. Principle components analysis (PCA) was used to identify and exclude individuals with non-European ancestry. Genome coverage was increased by imputation using SHAPEIT (14) and IMPUTE2 (15) with the 1000 Genomes Phase III reference panel (16) . In this study, expected dosages of the alleles of the 94 breast cancer risk variants were extracted from the imputed data.
Statistical Analysis
Polygenic risk scores were created to quantify the patients' genetic risk of breast cancer. For each patient, genotype dosages for the 94 breast cancer risk-increasing alleles were calculated and then summed across all the variants. Two types of risk score were calculated: For univariable analysis, ordinal logistic regression was used to test the association between the acute or individual late toxicity endpoints and polygenic risk score. Linear regression was used to test the association between STAT and risk score. Each genetic variant was also tested individually. For multivariable analysis, a residual analysis was performed (17) . Residuals from multivariable analyses of the two-year toxicity endpoints with non-genetic covariates, produced as part of the original RAPPER GWAS of late toxicity (11) , were used to analyze two-year toxicity. These residuals estimate the risk of toxicity not explained by available patient-and treatment-related factors including baseline symptoms that resulted from surgery and were present before radiotherapy. Residuals for acute toxicity and fiveyear toxicity were calculated from multivariable regression models including significant non-genetic factors as part of this study. Linear regression was used to evaluate the association between the residuals and both the genetic risk scores and the individual variants. The association between polygenic risk and baseline symptoms was assessed separately to confirm that adjustment for baseline symptoms would not substantially change the results. For the primary analysis, the polygenic risk scores were considered statistically significant if p-value<0.05. To reduce the chance of a false-positive association due to multiple testing, the individual genetic variants were deemed statistically significant if p-value<5 x 10 -4 .
Research.
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Results
Out of the 94 genetic variants known to increase the risk of breast cancer, 90 were genotyped or imputed successfully (r2>0.66) in the 1160 patients in the RAPPER cohort -details in Table 2 . Figure 1 shows the distributions of the un-weighted and weighted polygenic risk scores among all patients with late toxicity data available (N=1134), which approximate to a normal distribution in these samples.
The distributions of the nine different acute and late-arising toxicity endpoints (acute toxicity, telangiectasia, breast edema, photographically assessed shrinkage, induration, pigmentation, breast pain, breast sensitivity and a standardized total average toxicity (STAT) score) measured in this study are shown in Table 3 . Baseline symptoms that resulted from surgery and were present before radiotherapy were not associated with any of the genetic variants either individually or in the polygenic risk score.
The significant non-genetic factors associated with acute toxicity and the five-year toxicity endpoints are shown in Supplementary Table 3 .
None of the individual genetic variants were associated, at the pre-specified significance level of p<5 x 10 -4 , with acute toxicity or two-year toxicity in either univariable or multivariable analyses (Supplementary Table 4 , Supplementary Figures 1-9 Table 5 ).
Scatter plots comparing each variant's effect on breast cancer risk with their effects on STAT (overall toxicity score) at two years and five years are shown in Figure 2 . Scatter plots for all other toxicity endpoints can be found in Supplementary Figures 10-17 . Points in the top right hand quarters of the plots represent alleles associated with both increased breast cancer and radiation toxicity risk.
Conversely for points in the bottom right hand quarter, the allelic effects are opposite for breast cancer and radiation toxicity risk. The plots reveal no correlations between these confirmed breast cancer risk alleles and increased radiotherapy toxicity risk in this RAPPER cohort.
When the more statistically powerful polygenic risk scores were tested, there were no associations with acute toxicity (weighted p-values>0.30; un-weighted p-values>0.39) or any of the two-year toxicity endpoints (weighted p-values ≥0.13; un-weighted p-values≥0.17) or five-year endpoints (weighted p-values≥0.19; un-weighted p-values≥0.39) ( Table 4 ).
Discussion
The hypothesis behind this study was that common genetic variants known to increase the risk of breast cancer may also increase the likelihood of developing toxicity following radiotherapy for breast cancer.
We found no conclusive evidence supporting this hypothesis. One SNP, rs6964587, was identified as associated with increased breast edema at 5 years (OR=1.75; 95% CI=(1.30-2.49)). This SNP is a missense SNP lying in a coding region of the AKAP9 gene, which encodes the A kinase (PRKA) anchor protein 9 -a key component of signal transduction that contributes to carcinogenesis (2, 19, 20 is predicted to generate a M643I substitution in the AKAP9 protein sequence. Of note, a study by Han et al suggested that breast tumor cells secrete the AKAP9 protein in response to ionizing radiation (20) .
This SNP association merits further investigation in independent radiotherapy toxicity cohorts.
The nearest gene to each individual breast cancer risk locus studied is listed in Table 2 . For some of these, (marked with d or e ), the target gene and mode of action of the causal variant has been elucidated, but for the majority this process is still on-going. A few putative target breast cancer genes on the list (for example, CHEK2 and RAD51b) have known roles in DNA damage repair, but it is unlikely that the majority will prove to have similar functions. In this study of common low-penetrance breast cancer loci, the rare, more highly penetrant mutations in genes such as ATM, BRCA1, BRCA2 and TP53
were not genotyped and could not be included in this analysis. Investigation of these genes requires complete sequencing of the relevant genes and different statistical methods and is on-going. The link between radiosensitivity and cancer risk has been exemplified by ATM gene mutations, causing ataxiatelangiectasia, a cancer predisposing immunodeficiency syndrome characterized by extreme sensitivity to radiation and life-threatening radiotherapy toxicity (21) . Carriers of ATM gene mutations, including relatives of people with ataxia-telangiectasia, have an increased risk of breast cancer (22) . An in vitro radiosensitivity assay revealed that around 40% of breast cancer patients tested displayed evidence of increased radiosensitivity (7, 8, 23) . Another study demonstrated the heritability of enhanced chromosomal radiosensitivity in breast cancer families (6) .
This RAPPER study had a relatively small sample size. The original studies confirming the associations of the 94 genetic variants with increased breast cancer risk were performed in BCAC with over 100,000 study participants. In contrast, the RAPPER breast cohort comprises just fewer than 1,200 patients and the study had low power to detect a true association between individual variants and radiotherapy toxicity. Despite this, a single variant associated with an ~75% increased odds of breast edema five years following radiotherapy has been detected at a stringent statistical significance threshold. Future larger studies with greater power will be able to identify other individual SNPs that may be associated with radiotherapy toxicity. These studies could also explore whether the effect sizes of individual variants on breast cancer risk differ from those for radiation toxicity risk. Although this study was generally underpowered to detect individual variants, the study was well powered (87%) to detect an association between radiotherapy toxicity and a polygenic risk score. The 90 confirmed breast cancer variants, used in this study, have been estimated to explain 16% of the familial risk of breast cancer (3) and an earlier polygenic risk profile, which included a subset of 77 of these SNPs, demonstrated that women in the highest 1% of the risk score were 3.6 times more likely to develop breast cancer than women in the middle quintile (4). We have extended the polygenic risk profile to include 90 currently assayable breast cancer risk loci and have shown that they have no detectable predictive value for risk of radiation toxicity in women being treated for breast cancer. Our analysis was limited to women of European ancestry only and therefore the findings may not be generalizable to women of other ancestries.
In summary, our study found no evidence to support a suggestion that patients with a high polygenic risk of breast cancer have an increased likelihood of developing acute or late radiotherapy toxicity. The conclusion from this work is that it appears to be safe for breast cancer patients with a high polygenic risk of breast cancer to receive standard radiotherapy for breast cancer.
for early access to pre-published details of the breast cancer risk variants. We acknowledge NHS funding to the NIHR Biomedical Research Centre at The Royal Marsden and the ICR. 
